Focus Europe

October 4th - 2017 : A common platform to make treatment access easier for patients

According to EMA and EUnetHTA, set up a common platform in order to make communication with manufacturers easier. Thus, this collaboration tends to harmonize requirements for robust data useful both for Marketing Authorization and Health Technology Assessment.  

Industrials should as well require an early dialogue with these two organizations through a dedicated secretariat. The platform presents multiple benefits:
  • A formalized interaction between EMA and EUnetHTA in specific problem resolution
  • A better coordination with the creation of a taskforce dedicated to early dialogue
  • Simplifiedr logistics
Wim Goettsch, Executive Director at EUnetHTA, reports that early dialogue through the platform and provision of robust data will fill the need of the two organizations, which final purpose is to “support decisions at the national level”. 

Patient perspective also has to be integrated, considering that regulatory collaboration must in fine allow to make treatment more accessible to patients and develop innovation. 

Read More

Company News

22th September 2017 : The Nextep team will be present at ISPOR 20th Annual European Congress (4-8 November 2017)

You are welcom at the NEXTEP booth (number 115, Hall 4) in Glasgow for the 20th ISPOR European Congress from 4th to 8th November 2017.

Our team will be delighted to review collaboration opportunities especially regarding Patient Market Access strategy In Europe.

Feel free to contact us to set appointments.

Vincent Cheney, Senior Business Partner International
@ : 
Phone : +33 (0) 6 65 95 77 87

Isabelle Berard, Market Access Senior Manager
@ :
Phone : +33 (0) 6 58 27 99 85

Florian Benazet, Market Access Consultant
@ :

You will have the opportunity to review our posters during the following sessions :

Read More


International Pharma Express n°80 - September 13th - 2017

The cost of innovation: a conflicting issue

The annual EFPIA conference in Brussels had seen pharmaceutical companies and European institutions address issues that were in everyone’s mind: innovation and its cost.

As Jean-Christophe Tellier, CEO at UCB, recalls, European Union is still perceived as an innovation-prone area and should remain attractive. According to him, Europe necessarily has to support health care transformation and should be more oriented toward prevention and primary cares. He declares: “there is still too much unmet needs and problems of access to care”.

If incentive measures are necessary to foster innovation, Martin Seychell, European Commission’s deputy-director general for health, hopes to receive some feedback from drug firms that benefit from incentive schemes for orphan pediatric drugs.  He then denounced the behavior of companies that weaken healthcare systems by setting high prices for their products.

Mentioning a recent experiment, the Irish health minister exhorted European countries to tackle with such practices that restrain access to medicines. Germany set aside, reluctant to consider any kind of mandatory cooperation, most European ministers are convinced of the relevance of such a coalition, or a further regulatory framework for price negotiation.

Read More

Read More